Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Johnson & Johnson — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.1, while Johnson & Johnson trades at $260.77 (market cap $626.09B). The key difference: Johnson & Johnson pays a 2.06% dividend while YieldMax AMD Option Income Strategy ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | JNJ | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $267.24 |
52-Week Low | $29.80 | $172.78 |
Market Cap | — | $626.09B |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.66, up 2.47% with a bearish technical signal from moving averages. The ETF generates high weekly distributions but faces concerns about NAV erosion during AMD volatility. Recent Seeking Alpha analysis rates it HOLD, noting the strategy works best when AMD rises gradually rather than accelerating sharply.
Outlook remains cautious due to structural NAV erosion risks. The high-yield strategy provides income opportunity but requires careful timing. Key risks include AMD's performance volatility and the ETF's call spread strategy limitations during market downturns.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
